228 patents
Utility
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
7 Mar 23
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua Frederick, Ailin Bai, Vladimir Presnyak, Stephen Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Filed: 7 Sep 22
Utility
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
7 Mar 23
The disclosure features novel lipids and compositions involving the same.
Kerry E. Benenato, Mark Cornebise, Edward Hennessy, Ellalahewage S. Kumarasinghe
Filed: 19 May 21
Utility
Methods for therapeutic administration of messenger ribonucleic acid drugs
28 Feb 23
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
Filed: 29 Sep 20
Utility
Stabilized formulations of lipid nanoparticles
21 Feb 23
The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof.
Mark Brader
Filed: 8 Nov 17
Utility
Heterologous UTR Sequences for Enhanced mRNA Expression
16 Feb 23
mRNAs containing an exogenous open reading frame (ORF) flanked by a 5′ untranslated region (UTR) and a 3′ UTR is provided, wherein the 5′ and 3′ UTRs are derived from a naturally abundant mRNA in a tissue.
David H. Burkhardt, Romesh R. Subramanian, Christian Cobaugh
Filed: 21 Jun 22
Utility
Broad spectrum influenza virus vaccine
14 Feb 23
The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
Filed: 15 Mar 18
Utility
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
9 Feb 23
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
Filed: 27 May 22
Utility
Human Cytomegalovirus Vaccine
9 Feb 23
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 13 Jun 22
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
7 Feb 23
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain James McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 15 Apr 22
Utility
Methods for preparing particles and related compositions
31 Jan 23
Methods for preparing particles and related compositions are provided.
Michael H. Smith
Filed: 17 Aug 16
Utility
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
31 Jan 23
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Antonin De Fougerolles, Justin Guild
Filed: 20 Sep 19
Utility
Compositions and Methods for Delivery of Agents to Immune Cells
26 Jan 23
The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes.
Gilles BESIN, Luis BRITO, Stephen G. HOGE, Edward HENNESSY, Mark CORNEBISE, Kerry BENENATO, Staci SABNIS, Michael W. DANNEMAN
Filed: 18 May 22
Utility
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
26 Jan 23
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
Filed: 7 Sep 22
Utility
Infectious Disease Vaccines
19 Jan 23
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Filed: 5 May 22
Utility
Signal-sensor Polynucleotides for the Alteration of Cellular Phenotypes
19 Jan 23
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.
Stephen G. HOGE, Tirtha CHAKRABORTY, Joshua P. FREDERICK, Matthias JOHN, Antonin DE FOUGEROLLES
Filed: 29 Jan 21
Utility
Polynucleotides Encoding GLUCOSE-6-PHOSPHATASE for the Treatment of Glycogen Storage Disease
12 Jan 23
This disclosure relates to mRNA therapy for the treatment of glycogen storage disease type 1a, (GSD-Ia), and related symptoms such as hypoglycemia. mRNAs for use in the invention, when administered in vivo, encode human glucose-6-phosphatase (G6Pase or G6PC), and functional fragments and variants thereof. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of G6PC expression and/or activity in subjects. mRNA therapies of the invention further increase the glucose production, and reduce the abnormal accumulation of glycogen and/or glucose-6-phosphate associated with GSD-Ia.
Paolo G. V. Martini, Athanasios Dousis, Vladimir Presnyak, Jingsong Cao
Filed: 12 Sep 19
Utility
Seasonal Rna Influenza Virus Vaccines
5 Jan 23
The disclosure provides RNA vaccines for seasonal influenza virus as well as methods of using the vaccines.
Raffael Nachbagauer, Carole Henry, Patricia Jorquera
Filed: 10 Jan 22
Utility
Novel Headgroup Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
5 Jan 23
The disclosure features novel lipids and compositions involving the same.
Kerry E. BENENATO, Mark CORNEBISE, Edward HENNESSY, Andrew MCKENZIE
Filed: 18 Sep 20
Utility
Human cytomegalovirus vaccine
3 Jan 23
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 10 Dec 21
Utility
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
29 Dec 22
The disclosure features novel lipids and compositions involving the same.
Kerry E. BENENATO, Mark CORNEBISE, Edward HENNESSY
Filed: 19 Sep 19